Corvus Pharmaceuticals, Inc.
CRVS Real Time Price USDRecent trades of CRVS by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by CRVS's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Methods for detecting and treating cancers having adenosine pathway activation Oct. 15, 2024
-
Patent Title: Methods of treating cancer Jul. 02, 2024
-
Patent Title: Compounds and methods for modulating interleukin-2-inducible t-cell kinase Feb. 13, 2024
-
Patent Title: Humanized anti-cd73 antibodies Jan. 02, 2024
-
Patent Title: Pharmaceutical formulations Mar. 08, 2022
-
Patent Title: Compounds and methods for modulating adenosine a2b receptor and adenosine a2a receptor Feb. 22, 2022
-
Patent Title: Methods of treating cancer Jun. 22, 2021
-
Patent Title: Compounds and methods for modulating interleukin-2-inducible t-cell kinase May. 18, 2021
-
Patent Title: Methods of treating cancer Feb. 09, 2021
-
Patent Title: Compounds and methods for modulating bruton's tyrosine kinase Dec. 22, 2020
-
Patent Title: Humanized anti-cd73 antibodies Nov. 03, 2020
-
Patent Title: Anti-cd73 antibodies Oct. 06, 2020
-
Patent Title: Processes for making triazolo[4,5d] pyramidine derivatives and intermediates thereof May. 19, 2020
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of CRVS in WallStreetBets Daily Discussion
Recent insights relating to CRVS
Recent picks made for CRVS stock on CNBC
ETFs with the largest estimated holdings in CRVS
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CRVS Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.